Aclaris therapeutics announces $80 million private placement

Wayne, pa., nov. 18, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs) (the “company” or “aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. the private placement is expected to close on or about november 19, 2024, subject to the satisfaction of customary closing conditions.
ACRS Ratings Summary
ACRS Quant Ranking